S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma|
|CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells|
|Phase 2 Trial Of Binimetinib In NRAS Melanoma Shows Promising Clinical Activity|
|Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2015|
|Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 Congress|
|Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline|
|Array To Regain Worldwide Rights To Binimetinib (2014/12/3)|
|Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib|
|Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014|
|Foundation Medicine and Collaborators to Present New Clinical Data on FoundationOne® Heme at the American Society of Hematology Annual Meeting|
Click above to view more mutual fund data and stats for mek - Metals Creek Resources Corp.